Adaptive Biotechnologies CorporationADPTNASDAQ
Loading
Cash Generation ExpandingExpanding
Percentile Rank63
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-48.95M
↑ 46% vs avg
Percentile
P63
Within normal range
Streak
4 yr
Consecutive growthExpanding
Average
$-91.09M
Historical baseline
PeriodValueYoY Change
2025$-48.95M+50.5%
2024$-98.88M+40.8%
2023$-167.02M+16.6%
2022$-200.29M+21.3%
2021$-254.47M-51.0%
2020$-168.49M-186.8%
2019$194.20M+603.4%
2018$-38.58M-3.2%
2017$-37.36M-